Hetero Labs Ltd Vi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HETERO LABS LTD VI, and what generic and branded alternatives to HETERO LABS LTD VI drugs are available?
HETERO LABS LTD VI has four approved drugs.
Summary for Hetero Labs Ltd Vi
| US Patents: | 0 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Hetero Labs Ltd Vi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hetero Labs Ltd Vi | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 215460-001 | Jun 14, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Hetero Labs Ltd Vi | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 215460-002 | Jun 14, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Hetero Labs Ltd Vi | BORTEZOMIB | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 212204-001 | May 3, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Hetero Labs Ltd Vi | AZACITIDINE | azacitidine | POWDER;INTRAVENOUS, SUBCUTANEOUS | 215765-001 | Oct 15, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Hetero Labs Ltd Vi | DECITABINE | decitabine | INJECTABLE;INTRAVENOUS | 215355-001 | May 10, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
